These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 35773226)
1. Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacological Perturbations. Semenza GL Annu Rev Med; 2023 Jan; 74():307-319. PubMed ID: 35773226 [TBL] [Abstract][Full Text] [Related]
2. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Semenza GL Blood; 2009 Sep; 114(10):2015-9. PubMed ID: 19494350 [TBL] [Abstract][Full Text] [Related]
3. Update on mutations in the HIF: EPO pathway and their role in erythrocytosis. Lappin TR; Lee FS Blood Rev; 2019 Sep; 37():100590. PubMed ID: 31350093 [TBL] [Abstract][Full Text] [Related]
4. Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia. Packer M Am J Nephrol; 2024; 55(2):255-259. PubMed ID: 37231827 [TBL] [Abstract][Full Text] [Related]
5. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor. Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309 [TBL] [Abstract][Full Text] [Related]
6. The HIF pathway and erythrocytosis. Lee FS; Percy MJ Annu Rev Pathol; 2011; 6():165-92. PubMed ID: 20939709 [TBL] [Abstract][Full Text] [Related]
7. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease. Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538 [TBL] [Abstract][Full Text] [Related]
8. Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous? Strowitzki MJ; Cummins EP; Taylor CT Cells; 2019 Apr; 8(5):. PubMed ID: 31035491 [TBL] [Abstract][Full Text] [Related]
9. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia. Zuk A; Si Z; Loi S; Bommegowda S; Hoivik D; Danthi S; Molnar G; Csizmadia V; Rabinowitz M J Pharmacol Exp Ther; 2022 Oct; 383(1):11-24. PubMed ID: 35926869 [TBL] [Abstract][Full Text] [Related]
10. Erythrocytosis-associated HIF-2alpha mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor proline. Furlow PW; Percy MJ; Sutherland S; Bierl C; McMullin MF; Master SR; Lappin TR; Lee FS J Biol Chem; 2009 Apr; 284(14):9050-8. PubMed ID: 19208626 [TBL] [Abstract][Full Text] [Related]
11. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics. Kular D; Macdougall IC Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190 [TBL] [Abstract][Full Text] [Related]
12. Erythrocytosis associated with a novel missense mutation in the HIF2A gene. van Wijk R; Sutherland S; Van Wesel AC; Huizinga EG; Percy MJ; Bierings M; Lee FS Haematologica; 2010 May; 95(5):829-32. PubMed ID: 20007141 [TBL] [Abstract][Full Text] [Related]
13. Erythrocytosis and pulmonary hypertension in a mouse model of human HIF2A gain of function mutation. Tan Q; Kerestes H; Percy MJ; Pietrofesa R; Chen L; Khurana TS; Christofidou-Solomidou M; Lappin TR; Lee FS J Biol Chem; 2013 Jun; 288(24):17134-44. PubMed ID: 23640890 [TBL] [Abstract][Full Text] [Related]
14. Erythropoietin production by PDGFR-β(+) cells. Gerl K; Nolan KA; Karger C; Fuchs M; Wenger RH; Stolt CC; Willam C; Kurtz A; Kurt B Pflugers Arch; 2016 Aug; 468(8):1479-87. PubMed ID: 27220347 [TBL] [Abstract][Full Text] [Related]
16. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720 [TBL] [Abstract][Full Text] [Related]
17. TP0463518, a Novel Prolyl Hydroxylase Inhibitor, Specifically Induces Erythropoietin Production in the Liver. Kato S; Ochiai N; Takano H; Io F; Takayama N; Koretsune H; Kunioka EI; Uchida S; Yamamoto K J Pharmacol Exp Ther; 2019 Dec; 371(3):675-683. PubMed ID: 31585986 [TBL] [Abstract][Full Text] [Related]
18. VHL gene methylation contributes to excessive erythrocytosis in chronic mountain sickness rat model by upregulating the HIF-2α/EPO pathway. Yang M; Zhu M; Song K; Wuren T; Yan J; Ge RL; Ji L; Cui S Life Sci; 2021 Feb; 266():118873. PubMed ID: 33309718 [TBL] [Abstract][Full Text] [Related]
19. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma. Gong K; Zhang N; Zhang K; Na Y Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786 [TBL] [Abstract][Full Text] [Related]